Medical Genetics

Long-Term Monitoring and Your Future with MAD

At a Glance

Mandibuloacral dysplasia requires lifelong, personalized monitoring because heart, kidney, bone, metabolic, skin, and dental problems can develop over time. Regular surveillance can detect complications early, while prognosis varies by subtype, genetic variant, and organ function.

Living with Mandibuloacral Dysplasia (MAD) means managing a condition that is chronic and multisystem. Because symptoms change over time, the goal of long-term care is to stay ahead of complications through consistent surveillance ^[1]^[2]. While the diagnosis is lifelong, understanding the typical progression and having a clear monitoring plan can help you maintain your quality of life.

Expected Long-Term Outlook

Because MAD is exceptionally rare, “average” life expectancy numbers are difficult to calculate and may not represent your individual experience. Recent reviews of small groups of patients provide some context, but these vary significantly by subtype and should be interpreted as limited historical observations rather than a reliable prediction for you ^[3]:

Type A (MADA): Many individuals with MADA live well into adulthood. In one study of 31 patients, no deaths were reported, and a woman with genetically confirmed MADA was reported alive and active at age 59 ^[3]^[4].
Type B (MADB): This subtype can be more complex. In a small review of 21 patients, the median survival was estimated at 37 years, with kidney (renal) complications being the primary cause of death for those who passed away ^[3].
MADaM (MTX2): This subtype is newly recognized and appears to be more severe, involving early growth failure, severe high blood pressure, and kidney scarring ^[5]^[6]. Long-term survival statistics for this group are not yet well-established.

These historical statistics are based on tiny, selected groups and are subject to significant reporting limitations. They cannot provide a reliable prediction for an individual outcome, and should not be used to terrify or falsely reassure. Your prognosis depends heavily on your specific genetic variant, your organ findings, and the care you receive. It is also important to note that survival depends heavily on how much function the affected enzyme (ZMPSTE24) still has ^[7].

Recommended Surveillance Schedule

Proactive monitoring is the best way to catch “silent” issues like heart valve changes or kidney strain before they cause symptoms ^[8]. There is no universally established schedule for all MAD subtypes. The following is an individualized discussion framework; your clinician should adjust this schedule based on your age, subtype, baseline findings, and symptoms.

Example Frequency	Evaluation	Target System
Every 6–12 Months	Echocardiogram & ECG	Checks for heart valve calcification and heart muscle strength ^[9]^[8]
Every 6–12 Months	Blood Pressure Monitoring	Monitors for “silent” hypertension, especially in MADB and MTX2. May need more frequent assessment depending on risk ^[5]
Yearly	Metabolic Panel & Lipids	Checks for insulin resistance, diabetes, and high triglycerides ^[8]^[2]
Yearly	Urinalysis & Kidney Function	Screens for protein in the urine or signs of renal strain ^[8]^[3]
Every 1–2 Years	DEXA (Bone Density) Scan	Monitors for premature osteoporosis or bone thinning ^[10]
Yearly	Skin & Dental Check	Tracks skin changes, calcium nodules, and dental health ^[2]

Disease Progression in Adulthood

As you move into adulthood, the focus of MAD care often shifts from growth and skeletal development to metabolic and cardiovascular health ^[4].

Skeletal Stability: While bone changes like acro-osteolysis (thinning of finger tips) may progress, they often reach a point of relative stability in adulthood ^[4].
Metabolic Shifts: The loss of body fat (lipodystrophy) may become more pronounced, making it harder for the body to manage sugar and fats ^[2].
Cardiovascular Watch: Heart valve calcification is a slow process but requires consistent monitoring, as interventions like valve replacement may eventually be needed based on measured valve disease and specialist assessment ^[11].

Quality of Life and Psychological Well-Being

Living with a condition featuring early tissue changes can take a significant emotional toll. You may face challenges related to body image due to skin and fat-distribution changes, or frustration with physical limitations like joint stiffness ^[2].

Daily Management: Maintaining hand function is often a priority, especially if acro-osteolysis affects your grip or fine motor skills. Occupational therapy can provide tools to make daily tasks easier ^[2].
Mental Health: The burden of “constant monitoring” can lead to medical anxiety. Many patients find it helpful to work with a therapist who specializes in chronic or rare diseases ^[1].
Social Connection: Because you may never meet another person with MAD in your local community, connecting with rare disease support networks for laminopathies or lipodystrophies can reduce the sense of isolation ^[1].

Remember that research is ongoing. As we understand more about the biology of prelamin-A processing, new management strategies are being developed to help patients live longer, healthier lives ^[12].

Common questions in this guide

What tests are used to monitor mandibuloacral dysplasia over time?

A personalized plan may include an echocardiogram and ECG every 6–12 months, regular blood-pressure checks, and yearly blood tests for metabolism and blood fats, urine testing, and kidney-function tests. Bone-density scans may be done every 1–2 years, with yearly skin and dental checks. Your clinician may change the timing based on your subtype, age, symptoms, and earlier results.

What is the life expectancy or long-term outlook for someone with MAD?

The outlook varies with the MAD subtype, genetic variant, organ findings, and how much ZMPSTE24 enzyme activity remains. Many people with MADA have lived well into adulthood, while MADB has been associated with serious kidney complications; MADaM appears more severe, but long-term data are limited. Small historical studies cannot predict one person’s life expectancy.

Why are kidney checks important in MAD?

Kidney problems can develop without obvious symptoms and were the primary reported cause of death in a small review of people with MADB. Yearly urine and kidney-function testing can look for protein in the urine or other signs of kidney strain, with more frequent testing when needed.

How can MAD change during adulthood?

Adult care often shifts from growth and skeletal development toward metabolic and cardiovascular health. Fingertip bone loss called acro-osteolysis may continue but can become relatively stable, while loss of body fat may make it harder to manage blood sugar and blood fats. Heart-valve calcification can develop slowly and still requires regular monitoring.

Can heart valve problems from MAD require treatment?

Heart-valve calcification may progress slowly, and valve replacement could eventually be considered if valve disease becomes significant. The decision depends on echocardiogram findings, heart function, symptoms, and specialist assessment.

What support can help with daily life and emotional well-being in MAD?

Occupational therapy can help adapt daily tasks and preserve hand function when joint stiffness or fingertip bone loss affects grip. Physical therapy may support movement, and a therapist familiar with chronic or rare disease can help with medical anxiety or body-image concerns. Rare-disease support groups may also reduce isolation.

Get notified when new evidence is published on Mandibuloacral dysplasia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Key takeaways

MAD is a lifelong, multisystem condition, so its monitoring plan should be tailored to the person’s subtype, age, symptoms, and baseline findings.
Heart testing, blood-pressure checks, metabolic and lipid tests, urine and kidney testing, bone-density scans, and skin and dental checks help look for complications before symptoms appear.
Long-term outlook varies by subtype, genetic variant, organ findings, and remaining ZMPSTE24 enzyme function, and small historical studies cannot predict an individual’s outcome.
In adulthood, care often shifts toward metabolic and cardiovascular health, although skeletal changes such as acro-osteolysis may continue or stabilize.
Occupational or physical therapy, mental-health support, and rare-disease connections can help with hand function, mobility, anxiety, and isolation.

References (12)

1
Mutations Involved in Premature-Ageing Syndromes.
Coppedè F
The application of clinical genetics 2021; (14()):279-295 doi:10.2147/TACG.S273525.
PMID: 34103969
2
Mandibuloacral dysplasia type B (MADB): a cohort of eight patients from Suriname with a homozygous founder mutation in ZMPSTE24 (FACE1), clinical diagnostic criteria and management guidelines.
Hitzert MM, van der Crabben SN, Baldewsingh G, et al.
Orphanet journal of rare diseases 2019; (14(1)):294 doi:10.1186/s13023-019-1269-0.
PMID: 31856865
3
Life expectancy and causes of death in classical laminopathic progeroid syndromes: systematic review with individual-patient data synthesis.
López-Vila C, García-Cordeiro M, Estévez-Martínez L, et al.
Aging 2026; (18(1)):695-718 doi:10.18632/aging.206389.
PMID: 42329128
4
Mandibuloacral dysplasia and LMNA A529V mutation in Turkish patients with severe skeletal changes and absent breast development.
Ozer L, Unsal E, Aktuna S, et al.
Clinical dysmorphology 2016; (25(3)):91-7 doi:10.1097/MCD.0000000000000132.
PMID: 27100822
5
Loss of MTX2 causes mandibuloacral dysplasia and links mitochondrial dysfunction to altered nuclear morphology.
Elouej S, Harhouri K, Le Mao M, et al.
Nature communications 2020; (11(1)):4589 doi:10.1038/s41467-020-18146-9.
PMID: 32917887
6
Case report: A novel splice-site mutation of MTX2 gene caused mandibuloacral dysplasia progeroid syndrome: the first report from China and literature review.
Fu X, Chen S, Huang X, et al.
Frontiers in endocrinology 2024; (15()):1345067 doi:10.3389/fendo.2024.1345067.
PMID: 38544690
7
A Case of Restrictive Dermopathy With Atypical Cardiac Anomalies and a Novel ZMPSTE24 Variant.
Kındış E, Varol Ö
American journal of medical genetics. Part A 2026; (200(8)):1897-1900 doi:10.1002/ajmg.a.70149.
PMID: 41877632
8
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.
Brown RJ, Araujo-Vilar D, Cheung PT, et al.
The Journal of clinical endocrinology and metabolism 2016; (101(12)):4500-4511 doi:10.1210/jc.2016-2466.
PMID: 27710244
9
Mandibuloacral dysplasia type A in five tunisian patients.
R S, H M, M T, et al.
European journal of medical genetics 2021; (64(2)):104138 doi:10.1016/j.ejmg.2021.104138.
PMID: 33422685
10
Mandibuloacral dysplasia: A premature ageing disease with aspects of physiological ageing.
Cenni V, D'Apice MR, Garagnani P, et al.
Ageing research reviews 2018; (42()):1-13 doi:10.1016/j.arr.2017.12.001.
PMID: 29208544
11
Severe cardiac valvular calcification in two Chinese brothers with mandibuloacral dysplasia type A: a case report.
Guo Y, Zhang X, Meng Y, et al.
Frontiers in cardiovascular medicine 2025; (12()):1657197 doi:10.3389/fcvm.2025.1657197.
PMID: 41357091
12
The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.
Odinammadu KO, Shilagardi K, Tuminelli K, et al.
Nucleus (Austin, Tex.) 2023; (14(1)):2288476 doi:10.1080/19491034.2023.2288476.
PMID: 38050983

This page explains long-term monitoring and prognosis in mandibuloacral dysplasia for educational purposes only and does not constitute medical advice. Your care team should tailor surveillance to your subtype, genetic findings, organ health, and symptoms.